Organovo Holdings (ONVO) : Traders are bullish on Organovo Holdings (ONVO) as it has outperformed the S&P 500 by a wide margin of 3.34% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.03%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.58% in the last 1 week, and is up 1.25% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 2.16% and the 50-Day Moving Average is 1.78%.The 200 Day SMA reached 37.55% Organovo Holdings, Inc. is up 29.81% in the last 3-month period. Year-to-Date the stock performance stands at 62.65%.
Organovo Holdings (ONVO) stock is expected to deviate a maximum of $0.35 from the average target price of $4.75 for the short term period. 2 Street Experts have initiated coverage on the stock with the most promising target being $5 and the most muted being $5.
For the current week, the company shares have a recommendation consensus of Buy. Organovo Holdings (NYSEMKT:ONVO): The stock opened at $4 and touched an intraday high of $4.175 on Friday. During the day, the stock corrected to an intraday low of $3.95, however, the bulls stepped in and pushed the price higher to close in the green at $4.05 with a gain of 1.25% for the day. The total traded volume for the day was 1,359,726. The stock had closed at $4.05 in the previous trading session.
Organovo Holdings, Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Its platform, NovoGen Bioprinters, is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue, which can be used for predictive preclinical testing of drug compounds.